Sanofi Connect

Issue 1 Anticoagulation Matters:
Medical Prophylaxis Edition

Hear from A/Prof. Kerry Hitos, Director of the Westmead Research Centre for Evaluation of Surgical Outcomes, University of Sydney, Westmead Hospital.  

A/Prof. Kerry Hitos describes why Australian researchers have excellent reputations.


An individualised patient-centered approach for assessing VTE risk in medical patients is recommended by A/Prof. Kerry Hitos.


A/Prof. Kerry Hitos reviews the new ACSQH Clinical Care Standards and recommends practices that could see 100% of patients appropriately prophylaxed against VTE. 


VTE = venous thromboembolism. 

Date of preparation: March 2019. SM_SAN980. SAANZ.ENO.19.01.0069

*Clexane Safety Lock as an automatic safety lock system.

Further information is available on request from Sanofi.


PBS Information: CLEXANE®. General Benefit Antithrombotic agent. Refer to PBS schedule for full information.CLEXANE® with Automatic Safety Lock System. Refer to PBS schedule for full information. CLEXANE® FORTE. This product is not listed on the PBS.

Please review Product Information before prescribing Clexane. Full Product Information is available by calling 1800 818 806 or by clicking here.

sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.


Receive future issues of Anticoagulation Matters, compiled specifically for you.


Access patient information and resources on VTE and Clexane®.